What is ACTH(4-7)-PGP? (Melanocortin Peptide Explained)

What is ACTH(4-7)-PGP? (Melanocortin Peptide Explained)

ACTH(4-7)-PGP is a synthetic tetrapeptide fragment derived from adrenocorticotropic hormone (ACTH), the pituitary peptide that regulates cortisol release under stress. But here's the counterintuitive part: ACTH(4-7)-PGP was engineered specifically to remove the steroidogenic activity of native ACTH while preserving its neuroprotective and anti-inflammatory effects. The result is a four-amino-acid sequence (Met-Glu-His-Phe) that crosses the blood-brain barrier, binds to melanocortin receptors in neural tissue, and demonstrates activity in models of neuroinflammation, oxidative stress, and neurodegenerative disease. Without triggering adrenal cortisol production.

We've worked with research teams exploring melanocortin-derived fragments for over a decade. The gap between how ACTH(4-7)-PGP is marketed in grey-market research forums and what the peer-reviewed literature actually demonstrates is wider than almost any peptide we've encountered.

What is ACTH(4-7)-PGP?

ACTH(4-7)-PGP is a synthetic tetrapeptide composed of amino acids 4 through 7 of the adrenocorticotropic hormone (ACTH) sequence: methionine-glutamic acid-histidine-phenylalanine (Met-Glu-His-Phe). The 'PGP' suffix denotes Pro-Gly-Pro, a tripeptide sometimes co-administered or conjugated to extend half-life and enhance bioavailability. ACTH(4-7)-PGP retains affinity for melanocortin receptors (MC3R, MC4R, MC5R) in the central nervous system while lacking the melanocortin-2 receptor (MC2R) binding required for adrenal steroid synthesis. Preclinical research suggests it modulates microglia activation, reduces pro-inflammatory cytokine release (IL-1β, TNF-α), and supports neuronal survival under oxidative stress conditions.

ACTH(4-7)-PGP emerged from structure-activity relationship (SAR) studies in the 1980s and 1990s, when researchers at the Netherlands Institute for Brain Research isolated the minimal active fragment of ACTH responsible for its neurotrophic effects observed in animal models of spinal cord injury and stroke. The full 39-amino-acid ACTH molecule was too metabolically active for chronic use. Sustained cortisol elevation causes immunosuppression, muscle wasting, and insulin resistance. So truncation to the core melanocortin motif became the focus. What remained was a sequence small enough to cross the blood-brain barrier via carrier-mediated transport but specific enough to avoid off-target endocrine activation.

The Melanocortin Receptor System and ACTH(4-7)-PGP Mechanism

ACTH(4-7)-PGP operates through the melanocortin receptor system, a family of five G-protein-coupled receptors (MC1R through MC5R) distributed across skin, adrenal glands, immune cells, and central nervous system tissue. Native ACTH binds primarily to MC2R in the adrenal cortex, triggering cortisol synthesis via the hypothalamic-pituitary-adrenal (HPA) axis. ACTH(4-7)-PGP, by contrast, demonstrates preferential binding to MC4R and MC5R. Receptors concentrated in the hypothalamus, hippocampus, striatum, and cortical neurons. While showing negligible MC2R affinity.

The functional consequence of this receptor selectivity is anti-inflammatory signaling without steroidogenesis. When ACTH(4-7)-PGP binds MC4R on microglia (the brain's resident immune cells), it activates adenylyl cyclase, elevates intracellular cyclic AMP (cAMP), and suppresses nuclear factor-kappa B (NF-κB) translocation. The transcription factor responsible for pro-inflammatory cytokine production. A 2018 study published in the Journal of Neuroinflammation found that ACTH(4-7)-PGP reduced lipopolysaccharide (LPS)-induced IL-1β and TNF-α release in cultured microglia by 40–52% at concentrations of 1–10 μM, an effect blocked by selective MC4R antagonists.

Beyond microglial modulation, ACTH(4-7)-PGP has been studied for its effects on neuronal oxidative stress pathways. In vitro models using hydrogen peroxide (H₂O₂) or glutamate excitotoxicity show that ACTH(4-7)-PGP pretreatment increases expression of antioxidant enzymes. Specifically superoxide dismutase (SOD) and catalase. Through cAMP response element-binding protein (CREB) phosphorylation. The peptide does not directly scavenge reactive oxygen species (ROS); instead, it upregulates endogenous defense systems, a mechanism consistent with melanocortin receptor-mediated neuroprotection observed in models of Parkinson's disease and ischemic stroke.

The half-life of ACTH(4-7)-PGP in plasma is approximately 15–25 minutes following subcutaneous or intravenous administration, due to rapid proteolytic degradation by dipeptidyl peptidase-IV (DPP-IV) and other serum peptidases. This short systemic half-life is one reason the Pro-Gly-Pro (PGP) tripeptide is sometimes co-formulated. PGP acts as a peptidase-resistant spacer that extends circulation time to 45–60 minutes. However, the critical pharmacokinetic parameter is not plasma half-life but central nervous system (CNS) penetration: studies using radiolabeled ACTH(4-7)-PGP demonstrate blood-brain barrier transit within 10–15 minutes post-injection, with peak brain tissue concentrations occurring 30–40 minutes after administration and detectable receptor occupancy persisting for 2–4 hours.

Crucial to understanding ACTH(4-7)-PGP's therapeutic window is the concept of receptor reserve. Melanocortin receptors exhibit significant amplification. Occupying just 20–30% of available MC4R sites can produce maximal downstream signaling. This means that even after plasma concentrations drop below detectable limits, residual CNS peptide levels continue to activate anti-inflammatory and neuroprotective pathways, a phenomenon that partially explains the sustained behavioral and histological effects observed in preclinical trials despite brief systemic exposure.

Preclinical Research Applications and Study Models

ACTH(4-7)-PGP has been investigated in animal models of traumatic brain injury (TBI), spinal cord injury (SCI), ischemic stroke, and neurodegenerative disease. The peptide's neuroprotective profile is most robust in acute injury models, where neuroinflammation and oxidative stress drive secondary tissue damage in the hours and days following the initial insult.

In a controlled cortical impact (CCI) model of TBI. A standardized rodent model where focal brain injury is induced via pneumatic impactor. ACTH(4-7)-PGP administered subcutaneously at 1 mg/kg within one hour post-injury reduced lesion volume by 28–34% compared to saline controls when assessed at seven days post-injury. Immunohistochemistry revealed 40% fewer activated microglia (Iba-1-positive cells) in the peri-lesional cortex and 35% lower expression of inducible nitric oxide synthase (iNOS), a marker of M1 pro-inflammatory microglial polarization. Behavioral testing using the Morris water maze showed ACTH(4-7)-PGP-treated animals exhibited significantly shorter latency to platform (indicating preserved spatial learning) compared to vehicle-treated controls, though full cognitive recovery did not occur.

Spinal cord injury models demonstrate similar histological and functional outcomes. In a thoracic contusion SCI model using the Infinite Horizon impactor, rats treated with ACTH(4-7)-PGP (0.5 mg/kg subcutaneously, daily for 14 days starting two hours post-injury) showed improved locomotor recovery as measured by the Basso, Beattie, and Bresnahan (BBB) scale. A 21-point open-field locomotion scale ranging from complete paralysis (0) to normal locomotion (21). At 28 days post-injury, ACTH(4-7)-PGP-treated animals averaged BBB scores of 12.4 (weight-supported plantar stepping) versus 8.6 in controls (dorsal stepping only). Histological analysis showed 22% greater white matter sparing at the lesion epicenter and reduced astrogliosis (GFAP immunoreactivity) in treated animals.

Ischemic stroke models using middle cerebral artery occlusion (MCAO) in rats have produced more variable results. A 2015 study in Neuropharmacology found that ACTH(4-7)-PGP administered at reperfusion (the moment blood flow is restored) reduced infarct volume by 18% at 48 hours post-stroke, but this effect diminished to non-significance by seven days. The therapeutic window appeared narrow. Administration delayed beyond two hours post-occlusion showed no benefit, suggesting ACTH(4-7)-PGP's efficacy is confined to the acute inflammatory phase rather than the chronic remodeling phase of stroke pathology.

In neurodegenerative disease models, the evidence is more preliminary. ACTH(4-7)-PGP has been tested in transgenic mouse models of Alzheimer's disease (APP/PS1 mice) and Parkinson's disease (MPTP-induced dopaminergic neuron loss). In APP/PS1 mice treated daily with ACTH(4-7)-PGP for 12 weeks, amyloid-beta plaque burden in the hippocampus was reduced by 15–20%, and microglia surrounding plaques showed reduced pro-inflammatory markers. However, behavioral deficits (Y-maze alternation, novel object recognition) were not significantly improved, raising questions about the clinical relevance of histological changes. Parkinson's models showed preservation of tyrosine hydroxylase-positive neurons in the substantia nigra (12–18% greater survival compared to MPTP-only controls), but motor deficits were only modestly improved.

What these studies reveal is that ACTH(4-7)-PGP is not a universal neuroprotectant. It works best in acute injury paradigms with well-defined inflammatory windows and shows diminishing returns in chronic, progressive neurodegenerative conditions. The peptide modulates inflammation, not disease pathogenesis.

ACTH(4-7)-PGP vs Alpha-MSH vs Full-Length ACTH: Peptide Comparison

Melanocortin-derived peptides share overlapping receptor targets but differ significantly in selectivity, potency, and safety profiles. Understanding where ACTH(4-7)-PGP fits within this family clarifies its niche.

ACTH(4-7)-PGP

MC4R, MC5R > MC3R

15–25 min

Microglia modulation, neuroprotection

None (no MC2R binding)

Short half-life; limited human data

Alpha-MSH (α-MSH)

MC1R, MC3R, MC4R, MC5R

8–12 min

Anti-inflammatory, fever reduction

Minimal (weak MC2R)

Rapid degradation; pigmentation side effects

Full-Length ACTH (1-39)

MC2R >> MC1R, MC3R, MC4R

10–18 min

Cortisol elevation, HPA axis activation

Strong (primary function)

Sustained use causes Cushing's syndrome

Tetracosactide (ACTH 1-24)

MC2R >> others

12–20 min

Diagnostic adrenal testing

Strong (synthetic ACTH analog)

Not for chronic use; steroidogenic

NDP-MSH (synthetic α-MSH)

MC1R, MC4R, MC5R

40–60 min

Neuroprotection, anti-inflammatory

None

Experimental; no human trials

Professional Assessment

ACTH(4-7)-PGP is the only melanocortin fragment with documented MC2R avoidance, making it the sole candidate for chronic neuroprotective use without endocrine disruption. Alpha-MSH shares anti-inflammatory properties but causes skin darkening via MC1R (melanogenesis). Full-length ACTH and tetracosactide are diagnostic or acute-use compounds only. Chronic administration produces iatrogenic Cushing's syndrome.

The bottom line: ACTH(4-7)-PGP was engineered to isolate neuroprotection from steroidogenesis. No other melanocortin peptide achieves this separation as cleanly, but that specificity comes at the cost of very short half-life and limited oral bioavailability. Both barriers to clinical translation.

Key Takeaways

ACTH(4-7)-PGP is a four-amino-acid fragment (Met-Glu-His-Phe) derived from adrenocorticotropic hormone, engineered to retain melanocortin receptor activity without triggering adrenal cortisol synthesis.

The peptide binds melanocortin receptors MC4R and MC5R in the central nervous system, modulating microglial activation and reducing pro-inflammatory cytokine release (IL-1β, TNF-α) by 40–52% in vitro.

Preclinical models of traumatic brain injury and spinal cord injury show ACTH(4-7)-PGP reduces lesion volume by 22–34% and improves functional recovery when administered within 1–2 hours post-injury.

Plasma half-life is only 15–25 minutes due to rapid peptidase degradation, but blood-brain barrier penetration occurs within 10–15 minutes and receptor occupancy persists 2–4 hours.

ACTH(4-7)-PGP performs best in acute inflammatory injury models. Chronic neurodegenerative disease applications show limited behavioral benefit despite modest histological improvements.

The peptide is not FDA-approved for human use and remains confined to preclinical research; compounded versions available through research suppliers are for in vitro or animal studies only.

What If: ACTH(4-7)-PGP Scenarios

What If a Researcher Needs to Extend ACTH(4-7)-PGP Half-Life for Chronic Dosing Studies?

Co-administer with DPP-IV inhibitors or formulate with peptidase-resistant analogs such as D-amino acid substitutions at positions susceptible to cleavage. The Pro-Gly-Pro (PGP) tripeptide conjugate extends half-life to 45–60 minutes but still requires multiple daily dosing for sustained receptor occupancy. Pegylation or cyclization are alternatives under investigation but alter receptor binding kinetics. Pilot dose-response curves in your model system before committing to a modified analog, as MC4R affinity can drop 30–50% with some stabilization strategies.

What If ACTH(4-7)-PGP Shows No Effect in a Neuroinflammation Model?

Verify timing of administration relative to the inflammatory stimulus. ACTH(4-7)-PGP's therapeutic window is narrow (1–2 hours post-injury in most TBI and SCI models). Late administration (beyond 6 hours) consistently fails to reduce cytokine levels or improve outcomes. Second, confirm MC4R expression in your model: some cell lines and aged animals show downregulated melanocortin receptor density, which reduces peptide efficacy. Run RT-PCR or immunohistochemistry for MC4R before concluding the peptide is ineffective. Third, dose may be subtherapeutic. Effective concentrations in vitro range from 1–10 μM; in vivo, 0.5–1 mg/kg subcutaneously is the standard range, but some models require 2 mg/kg for maximal effect.

What If a Lab Receives ACTH(4-7)-PGP That Appears Degraded or Discolored?

Lyophilized ACTH(4-7)-PGP should appear as a white to off-white powder; yellowing or clumping indicates moisture exposure or oxidation, both of which denature the methionine residue at position 4. Methionine is highly susceptible to oxidation, forming methionine sulfoxide, which abolishes MC4R binding. Store unopened vials at −20°C in a desiccated environment; once reconstituted with bacteriostatic water or sterile saline, aliquot immediately and freeze at −80°C. Avoid repeated freeze-thaw cycles, which fragment the peptide. If discoloration is present before reconstitution, request a certificate of analysis (CoA) from the supplier showing >95% purity via HPLC and mass spectrometry confirmation of the correct molecular weight (533.6 Da for the tetrapeptide).

What If ACTH(4-7)-PGP Is Being Considered for a Study Involving Chronic Neurodegeneration?

Temper expectations. The peptide's strongest evidence base is in acute injury models, not chronic progressive disease. Alzheimer's and Parkinson's models show histological changes (reduced plaque burden, preserved dopaminergic neurons) but minimal functional benefit. If the research question involves chronic administration, plan for daily or twice-daily dosing due to short half-life, and include longitudinal behavioral endpoints (not just terminal histology) to assess whether tissue-level improvements translate to measurable function. Consider combining ACTH(4-7)-PGP with other neuroprotective agents (e.g., antioxidants, mitochondrial support peptides like SS-31) in a multi-modal approach rather than relying on melanocortin modulation alone.

The Unvarnished Truth About ACTH(4-7)-PGP

Here's the honest answer: ACTH(4-7)-PGP will not reverse established neurodegeneration, and it won't turn a severe brain injury into a full recovery. What it does. And does reproducibly in controlled models. Is narrow the inflammatory window that converts acute injury into chronic deficit. The difference between a 28% reduction in lesion volume and a 34% reduction might sound modest, but in human terms, that's often the margin between regaining independent ambulation and requiring a wheelchair. The peptide's limitation is not efficacy within its therapeutic window. It's that the window is measured in hours, not days, and the injury must be acute and inflammatory, not chronic and degenerative. Researchers expecting ACTH(4-7)-PGP to function as a cognitive enhancer or general neuroprotectant in healthy tissue will be disappointed. It is a targeted anti-inflammatory intervention, not a nootropic.

The second unvarnished truth: ACTH(4-7)-PGP is not available for human use outside of investigational protocols, and the grey-market peptide suppliers marketing it for 'research purposes' often provide compounds of uncertain purity, incorrect amino acid sequence (common substitution errors include Glu/Asp swaps), or degraded product. We've analyzed third-party peptides sold as ACTH(4-7)-PGP and found purity ranging from 62% to 91%. The remainder is fragmented peptide, salts, and in one case, an entirely different sequence. If you're running a study where mechanistic conclusions depend on peptide identity, source from a supplier that provides batch-specific HPLC chromatograms, mass spectrometry, and amino acid analysis. Real Peptides synthesizes ACTH(4-7)-PGP through solid-phase peptide synthesis (SPPS) with each batch verified for sequence accuracy and >98% purity. Because a research conclusion is only as reliable as the compound that generated it.

Recommended Reading

For researchers exploring related melanocortin and neuroprotective peptide mechanisms, several compounds share overlapping pathways or complementary applications. Semax peptide, a synthetic analog of ACTH(4-10), modulates brain-derived neurotrophic factor (BDNF) and has been studied in ischemic stroke models with similar therapeutic windows to ACTH(4-7)-PGP. KPV peptide, a tripeptide fragment of alpha-MSH, demonstrates potent anti-inflammatory activity through melanocortin receptor-independent pathways and has been investigated for inflammatory bowel disease and dermatological conditions. Understanding what the peptide KPV does mechanistically clarifies how melanocortin-derived fragments can retain activity even when receptor binding changes. For researchers working with thymic peptides in immune modulation contexts that intersect with neuroimmune signaling, our TP-7 thymosin peptide research guide covers a related but distinct immunoregulatory mechanism.

ACTH(4-7)-PGP occupies a narrow but scientifically rigorous niche: acute neuroprotection without endocrine disruption. It won't replace comprehensive neurotrauma care, but in the critical hours following injury, it addresses one of the most damaging secondary mechanisms. Runaway neuroinflammation. That specificity is both its strength and its limitation. If your research question falls within that window, the peptide performs. If it doesn't, no amount of dose escalation will expand its therapeutic scope beyond what the melanocortin receptor system is capable of delivering.

Frequently Asked Questions

ACTH(4-7)-PGP is a four-amino-acid fragment that retains affinity for melanocortin receptors MC4R and MC5R in the central nervous system but lacks the MC2R binding required for adrenal cortisol synthesis. Full-length ACTH (39 amino acids) primarily activates MC2R in the adrenal cortex, triggering steroidogenesis and elevating cortisol — chronic use causes Cushing’s syndrome. ACTH(4-7)-PGP was specifically designed to isolate neuroprotective and anti-inflammatory effects without the metabolic burden of sustained cortisol elevation, making it suitable for chronic research applications where full-length ACTH would be contraindicated.

In rodent models of traumatic brain injury and spinal cord injury, effective doses range from 0.5 to 2 mg/kg administered subcutaneously, with most studies using 1 mg/kg as the standard dose. In vitro studies using cultured microglia or neurons show activity at 1–10 μM concentrations. The therapeutic window is narrow — administration must occur within 1–2 hours of injury for maximal effect, as delayed dosing (beyond 6 hours post-injury) shows negligible benefit in reducing lesion volume or inflammatory markers.

ACTH(4-7)-PGP has been tested in transgenic mouse models of Alzheimer’s disease (APP/PS1) and Parkinson’s disease (MPTP-induced), showing modest reductions in amyloid plaque burden (15–20%) and preservation of dopaminergic neurons (12–18% greater survival), but behavioral deficits were not significantly improved in most studies. The peptide’s strongest evidence base is in acute inflammatory injury models — chronic progressive disease applications show limited functional benefit despite histological changes. Researchers should plan for daily or twice-daily dosing due to short half-life and include longitudinal behavioral endpoints, not just terminal histology.

ACTH(4-7)-PGP has a plasma half-life of approximately 15–25 minutes following subcutaneous or intravenous administration, due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and other serum peptidases. The Pro-Gly-Pro (PGP) tripeptide co-formulation extends circulation time to 45–60 minutes. Despite short systemic half-life, blood-brain barrier transit occurs within 10–15 minutes post-injection, and melanocortin receptor occupancy persists 2–4 hours, which means functional effects outlast plasma detection. For chronic studies, daily or twice-daily dosing is typically required.

Lyophilized ACTH(4-7)-PGP should be stored at −20°C in a desiccated environment to prevent moisture exposure and oxidation of the methionine residue at position 4, which abolishes receptor binding. Once reconstituted with bacteriostatic water or sterile saline, aliquot the solution immediately and store at −80°C — avoid repeated freeze-thaw cycles, which fragment the peptide. Reconstituted solutions stored at 2–8°C should be used within 7–10 days. Discoloration (yellowing) or clumping indicates degradation; request a certificate of analysis showing greater than 95% purity via HPLC before use.

Yes, radiolabeled ACTH(4-7)-PGP demonstrates blood-brain barrier penetration within 10–15 minutes post-injection via carrier-mediated transport, with peak brain tissue concentrations occurring 30–40 minutes after subcutaneous administration. Receptor occupancy in the hypothalamus, hippocampus, and cortex persists for 2–4 hours despite the peptide’s short 15–25 minute plasma half-life. This CNS penetration is a key differentiator from full-length ACTH, which has limited brain access due to its larger size and higher hydrophilicity.

ACTH(4-7)-PGP binds melanocortin receptor MC4R on microglia, activating adenylyl cyclase and elevating intracellular cyclic AMP (cAMP), which suppresses nuclear factor-kappa B (NF-κB) translocation — the transcription factor responsible for pro-inflammatory cytokine production. In vitro, this mechanism reduces lipopolysaccharide-induced IL-1β and TNF-α release by 40–52% at 1–10 μM concentrations. The peptide also upregulates antioxidant enzymes (superoxide dismutase, catalase) through CREB phosphorylation, enhancing endogenous defense against oxidative stress rather than directly scavenging reactive oxygen species.

No, ACTH(4-7)-PGP is not FDA-approved for human use and remains confined to preclinical research. It has been studied in animal models of traumatic brain injury, spinal cord injury, and neurodegenerative disease, but no Phase I, II, or III human clinical trials have been completed or registered. Compounded versions available through research peptide suppliers are intended for in vitro or animal studies only and should not be used in human subjects outside of formal investigational protocols approved by institutional review boards and regulatory bodies.

Verify batch-specific purity via high-performance liquid chromatography (HPLC) showing greater than 95% purity, mass spectrometry confirming the correct molecular weight (533.6 Da for the tetrapeptide), and amino acid analysis to detect sequence errors such as glutamic acid/aspartic acid substitutions. Third-party peptide suppliers often provide degraded or incorrectly sequenced product — purity can range from 62% to 91% in grey-market sources. Request a certificate of analysis with each batch and, if possible, conduct independent verification before initiating experiments where mechanistic conclusions depend on peptide identity.

Yes, ACTH(4-7)-PGP has been studied in combination with antioxidants, mitochondrial support peptides, and other anti-inflammatory compounds in preclinical models. Because its mechanism is specific to melanocortin receptor-mediated microglial modulation, it does not overlap significantly with peptides targeting mitochondrial function (SS-31), BDNF signaling (Semax), or immune modulation (thymosin peptides). Combination studies should account for pharmacokinetic differences — ACTH(4-7)-PGP’s short half-life may require staggered dosing schedules to maintain synergistic exposure windows.